Dual Targeting of the HER2 Receptor

Clinical Pearls

Aditya Bardia, MD, MPH, attending physician, Massachusetts General Hospital, Harvard Medical School, discusses the dual targeting of the HER2 receptor in patients with breast cancer.

• Dual targeting of the HER2 receptor proved to better than single targeting, resulting in an improvement in pathological complete remission
• Presence of a pathological complete remission correlated with increased disease-free survival and overall survival in patients with hormone receptor-positive and hormone receptor-negative disease